Adjuvant therapy for early breast cancer: where do we stand today?

MedGenMed. 2003 Jun 18;5(2):17.
No abstract available

Publication types

  • Congress
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / prevention & control*
  • Chemotherapy, Adjuvant / trends
  • Drug Administration Schedule
  • Drug Resistance, Neoplasm
  • ErbB Receptors / immunology
  • Female
  • Humans
  • Neoplasm Staging / standards
  • Neoplasm Staging / trends
  • Oncogene Proteins v-erbB / immunology
  • Risk Factors
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Oncogene Proteins v-erbB
  • ErbB Receptors
  • Trastuzumab